drugset / Trial / NCT04078152
Durvalumab Long-Term Safety and Efficacy Study
Phase 4
Completed
163 enrolled
AstraZeneca
CISCRP · collabIQVIA Pty Ltd · collabMedidata Solutions · collabParexel · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.
Timeline
- Start
- 2019-09-05
- Primary completion
- 2022-10-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |